JCI's Conversations with Giants in Medicine: Bruce Beutler

Biologists and Doctors
10 followers
Hello, I'm Ushma Neal with the Journal of Clinical Investigation here to introduce the next in our
series of conversations with giants in medicine. Our next giant is Dr. Bruce Boitler of the
University of Texas Southwestern Medical School. A legend within the field of innate immunity,
Boitler is best known for two seminal discoveries. First, identifying mouse tumor necrosis factor
and demonstrating a role for the inflammatory responses and also for discovering Tollreich
receptor 4, the receptor for lipopolysaccharide. With this discovery, later rewarded with the
2011 Nobel Prize in Medicine, we finally understood how immune cells can recognize
and react to bacteria. Thank you so much for joining us and I look forward to hearing a
little bit about your particular path through medicine. Thanks very much, it's a pleasure to
be here. Could you start by telling me a little bit about where you grew up and your parents?
Yes, certainly. I grew up in Southern California and actually was born here in Chicago, but from
the age of two I was raised in Southern California. My father was a biomedical researcher himself,
Ernest Boitler, very renowned hematologist with eclectic interests, interested in the genetics
of anemia, especially G6PD deficiency and later glycolipid storage diseases as well,
iron deficiency, to some extent cancer. He worked on all of those things and really did outstanding
work rather than shallow work which many people do if they try to cover such a broad area.
Most definitely he encouraged an interest in science from an early age, in my own case.
Did that interest focus on hematology and anemia or botany?
I started off with a very broad interest in nature and I remember being fascinated by animals
from the time I was a small child, thinking how interesting it was that they could move and showed
properties of free will and were really a lot like we were. And I got to thinking about how
remarkable it was that molecules could organize themselves in that way, that life could co-opt
inanimate material and make it a part of itself, and I wanted to understand that. But also I was
just very much taken by the beauty of nature and by a constant interest in animals. And at some
point my father tried to influence me a little bit, I would say, and he pointed out that all of
my birding expeditions and hiking and so forth weren't really science, I was merely being
observational. And he invited me to work in his lab, which excited me very much, I was certainly
eager to do that. And from the age of 14 or so I started working in his laboratory through the
whole summer and then on weekends thereafter during the school year, and I got to be quite
familiar with how things were done there. I learned how to assay erythrocyte enzymes
using linked reactions with NADPH and NAD, and I learned to do electrophoresis in starch gels
to purify proteins. And all of this was very important to me later on, but I did definitely
veer toward real science under his direction. Now you went to college really young, you were 16,
right, and finished very quickly as well. Yes, I did that. Again I was trying to emulate my father
to some degree, because he went to college at 15 and finished medical school at 21, and I always
set that as a kind of standard to be followed for academic excellence. But also I remember just
being impatient to start really practicing science instead of being mostly an observer and a trainee,
and I thought remarkable things were happening. People were beginning to clone cDNAs by the time
I was in college, and molecular biology was undergoing a real revolution, and I wanted to be
a part of all that. I've heard you say the train of science was leaving without you, so you're
eager to be on that. Now during college you also had two influential mentors who you worked with.
Yes, actually there were quite a number, but maybe the two premier mentors of that time
would be Susumu Ono, who was a mammalian geneticist, also with a very strong interest
in immunology, which he kind of infected me with, and also Dan Lindsley, a Drosophila geneticist at
UCSD. They were real role models for me after my father, I would say. And sort of laid out for
you some of the steps in how you do genetic investigations, right? Definitely. I have to
admit that in college I didn't completely get it about genetics. That took longer.
And some of us still don't get it. We should definitely come back to that in that case.
When I was in college, Dan Lindsley of course was very excited about genetics. He studied
spermatogenesis and spermiogenesis in the fly, but you have to remember that was a time
where one could map genes and set them in order and do complementation studies and so forth. But
that was where the understanding generally ended, because you couldn't track down mutations in the
way you could subsequently. So I thought naively that with the solution of the genetic code,
genetics had reached the summit of what it could achieve. And I became interested first in
biochemistry and in immunology, to which I also had a lot of exposure in those days.
But I returned to genetics later on, seeing what a powerful approach it was to start with phenotype
and then track down the precise molecular cause, which did become possible.
But off you went to medical school, which you finished rather quickly.
Why did you choose University of Chicago for your studies?
I applied to many universities, and unfortunately I was only accepted to one. Maybe because I was
only 18 years old when I was applying. Also, I was unabashedly saying to all of the people who
interviewed me that I was really interested in science. And I think the attitude was,
in that case, why don't you get a PhD? I had advice to the contrary, again, from my father
in those days. He felt that if I wanted really to be a biomedical scientist, I should study medicine.
I should learn at least what the big challenges were. I should understand anatomy, physiology,
pathology, pharmacology. Knowing all of those things, I'd be in a position to work on
almost any problem I chose. Now, you went into medical school knowing that you were going to
at least do a residency. But do you think that it helped you in terms of your scientific approach?
Yes, I do. I think certainly it did help me. And in a way, when we do the work we do today,
creating mutations in mice, finding abnormalities of the immune system and tracking them down,
we are creating diseases. And physicians have always had to cope with diseases and try to
understand them. So it should be second nature to a physician, in a way, to take a forward
genetic approach and to try to understand the system by damaging it again and again and again
until you finally can deconstruct it. You chose UT Southwestern for your
internship and residency in neurology. Why? And was there anything about that place that then,
do you think, attracted you to come back later for your career?
Well, there I did have some choices. And I ranked UT Southwestern first. And I did it because I
thought that if I was going to do a residency, it should be a very tough residency, one where I
would really be challenged and I'd learn all I could about internal medicine and then neurology
in the shortest possible time. And I certainly was not disappointed in that regard.
It was a very stringent experience being an intern at Parkland Hospital. But that was the
reason I went, because it was hard. After your residency, you decided to
do some postdoctoral research with Tony Sarami at Rockefeller. So why did you choose,
at that time, to be working on what was thought to be coquectin, a muscle-wasting protein?
When I arrived in that lab, I had a choice to work either on that or on non-enzymatic glycosylation
in diabetes. And I chose to work on the coquectin project because I felt I could purify the protein.
It seemed another challenge to me. And when I began to assay it and to define the best conditions
for an assay, there was a very strong signal and I thought this should be a snap. And in fact,
it did go quite quickly. It took about a year to purify it to homogeneity and to sequence it.
Which turned out to be the mouse version of tumor necrosis factor.
Exactly right. Now, there I actually was surprised because it had been said in the
lab that they had ruled that out, that they had done assays for TNF activity and coquectin
preparations and for coquectin activity and TNF preparations, and they found no relationship
between the two. But there it was. So you actually ended up becoming sort
of the prototypical translational researcher because later you went on to develop some
recombinant molecules to antagonize TNF, which would later become a TAN receptor, Enbrel.
Yes.
That must have been tremendously satisfying.
Well, yes, it was. At a certain stage I did do that. I had the idea that antibodies against TNF,
which I had raised and used in mice, and I knew their effects quite well,
probably wouldn't be useful in humans because I thought humans would always begin to make
antibodies against monoclonal antibodies of murine origin. I thought that would be true
even if they were made chimeric or even if they were humanized. Whatever residuum of mouse
protein was left would be immunogenic. And I was wrong there. It turned out that many people do
tolerate chimeric antibodies like Remicade, but I didn't know that. That was all far in the future.
And I thought how to make a molecule that's really non-antigenic, highly specific,
and will block TNF. And others had cloned the TNF receptors by that time, David Goodell at
Genentech and David Wallach at the Weizmann Institute. And so I decided to make a chimeric
molecule with the ectodomain of the receptor hooked to an IgG molecule. And it worked better
than I expected. It was far more avid in binding TNF than a monovalent receptor fragment,
and it was very stable in vivo, and it made just the perfect drug in the end.
Excellent. I know we skipped ahead a little bit, but before that happened, you transitioned back
to Dallas to your first lab as an HHMI-funded investigator. That's right. So what were the
struggles like when you were first establishing your own lab? Very interesting. I felt a tremendous
sense of freedom because here I had my own lab, and I could build it and direct the research
however I wanted, and that was all very good. But suddenly I was confronting a new set of problems,
and I realized that scientific ability was no longer completely the issue,
and I had to deal with people to lead them in a certain way, get them excited about the things
that I was excited about, and make them work as a team to the extent that I could.
And that involved an entirely different skill set. Did you decide when you were establishing
your lab to switch focus a little bit from TNF to deciding or trying to sort out what the LPS
receptor was? Yes, and this was a gradual process. At first, it was something that I just wondered
about. I was familiar with the C3HHEJ mice that were endotoxin-resistant, and it was speculated
quite widely that they had a mutation in the LPS receptor, and nobody knew what that receptor was.
And I thought that's very peculiar, because here it is, the mid-1980s, and LPS has been around
nearly a hundred years now. And when I thought about it, I realized that nobody understood how
microbes were perceived in general, how macrophages, neutrophils, really knew when an infection was
in progress. And that elevated the stature of the question in my mind. So I first worked on it in
a very back-burner sort of way, starting maybe in about 1986 or 87. We began cross-immunizing
C3HHEJ mice with C3HHEN cells and vice versa, hoping to raise an antibody that would detect
the difference. And that never worked. And we also began looking proteomically, because these
were things I knew very well how to do. I thought maybe I could see a protein that was just missing
in the HEJ membrane fraction, and that never showed up. And we tried also cDNA cloning.
And I began incorporating more and more people into the project, but it was going nowhere
by those methods. And that was when I really returned to genetics, because I was very well
aware of positional cloning. And it seemed that every week or two, a new disease gene would be
positionally cloned in the human. And I thought, why not try to apply this strategy to this phenotype
in the mouse? So given the lack of what we take for granted now of current-day technologies,
it seems like you had to exhaust every different avenue towards trying to actually find it.
Yes, it was something I tried to avoid, positional cloning. And then all the same,
when I did start it, I got completely addicted to it. It was something so compelling,
the idea that you could start with a strong phenotype and gradually restrict the area of the
DNA to a smaller and smaller region, and then clone all of it, and then find the gene.
And of course, every stage of that is very hard. And even the mapping phase, the first phase of
narrowing the interval, is very difficult. And after you've done a few hundred meiosis,
let alone a few thousand, you just can't turn your back on it anymore. It gets to be
something completely addictive. Well, I noted from your Nobel
retrospective on not only the history, but your own autobiography, that you noted that you had
covered about 90% of the gene before you finally landed on TLR4.
Yes, that was a piece of bad luck. I think we did everything right. We narrowed the interval.
We started really in the middle of the contig that we built, and worked toward the margins,
because the middle would be the area of highest probability. And yet,
it turned out to be really quite far toward one of the markers at the edge.
I also read that you bought your own sequencer to help do this,
and that you later donated to the San Diego Zoo.
That's correct. That's right. It was a now antiquated slab gel sequencer, but it was
all we had in those days. And in fact, it was on that machine that the mutation was found.
If only you could get it back, right?
Yes, actually, I do want it back. And we've made inquiries,
but nobody seems to know what happened to it, and it may be in a landfill somewhere.
It could otherwise go in the Smithsonian, right?
Now, can you describe how it felt to actually land on TLR4?
Oh yes, I can tell you exactly. It was something that happened rather late at night,
maybe around 9.30 or so at night. I was back at home in my study, and I was looking over
the day's BLAST results, and we'd been through a long dry spell where we had just seen nothing
in the other backs approaching the margin. And I was getting very anxious because I knew that
either we had to find the mutation soon, or we had mapped incorrectly and we were just in the
wrong region of the genome. And that was almost unthinkable, but I do remember discussing with
Alexander Poltorak, who was the lead postdoc working with me on that project, the possibility
that we would have to just go past our limiting markers and keep looking up and down the chromosome
until we found it. And that was a really daunting prospect. Anyway, suddenly there was a very strong
hit with the BLAST search, and nearly perfect identity, over 600 or so nucleotides. And that
was a stronger match than I'd seen anywhere in the contig before. And within a few minutes, there
was another hit with the same gene. We were in a back called I17, and we had just begun to explore
it. And these two hits were both at different ends of the gene, which was very lucky for technical
reasons, because it enabled us to know the sequence and make primers and amplify the whole thing.
But I was very excited. I was hyperventilating. I was kind of shaking. I made a phone call
immediately to Alexander, and I could hardly tell him what I had seen because I was so excited about
it. And the reason to be excited was partly the nature of this gene, that it had leucine-rich
repeats, and therefore was similar to CD14, which was another protein known to be required for
LPS sensing, though not the transmembrane receptor. And I thought that made a good story.
And also, it had a cytoplasmic domain similar to IL-1 receptor, which wound up also in the same
list of hits in the BLAST search with one of the fragments that we had analyzed. And of course,
that is an inflammatory receptor that's known to activate NF-kappa-B. And I had a vague memory,
which I confirmed in a few minutes, that someone in France had earlier looked at toll and found
that it was needed for flies to resist fungal infection. And here I knew that TLR4, if this was
indeed the gene, would be required to resist gram-negative bacterial infection. So it made a
beautiful parallel evolutionary story. So all these things were very exciting, but we had certainly
to find the mutation. And we had made up nice stories about all the other genes or pseudogenes
that were in our contig before. Now, when you actually found it, you were in a bit of a hard
state, given that HHMI had just told you that they weren't going to support the research anymore.
Correct. So it must have been that much sweeter to have actually found it.
It was a great relief, and it was somewhat sweet for that reason. It still felt like quite a blow
that we had really focused on a tough problem, and that was what they said they liked to support,
and yet they had cut us off. But certainly I didn't feel devastated as I had a couple of
months earlier when I learned that news. High risk, high reward, right?
Yes. Now, was it soon after that that you
decided to move to California to the Scripps Research Institute?
Yes, I did. I wanted to go to California for several reasons. First, I love California.
It's where I grew up, and it all seems very familiar to me. Second, my father was at the
Scripps Research Institute. I'd always been close to him, talked to him almost every day. In fact,
he was doing his own positional cloning work at the same time on the hemochromatosis gene
of humans, and we would talk back and forth each about how the other project was going.
So I thought I could have a nice, close relationship with him there. Also, Richard
invited me to come there. He was someone who had long been in the LPS field,
made great contributions to it, discovered the role of CD14 in LPS sensing, and he wanted me
to be there. He made me a very generous offer, so I decided to go.
It was there that you first found out that you won the Nobel Prize by email,
right? At two o'clock in the morning. Yes, that's correct.
Can you tell us a little bit about the hoopla that surrounded that announcement?
Well, I was between moving from Scripps and back to Dallas. I was actually at both institutions and
was about to fly to Dallas later that morning. But I happened to have come back from Hong Kong,
and there I shared the Shaw Prize with Jules Hoffman and Ruslan Medzhitov,
and I was kind of jet-lagged. The day before the morning of the Nobel, my big brother, Earl,
also is in a biomedically-related area because he developed bibliographic software
for reference retrieval, a program called Reference Manager that many people may use.
No idea. We all use it every day. I see. Well, that's good to know.
He sold the company, but in any case, that was originally his program and my father's.
He had asked me in the casual chiding manner of a big brother,
you think you're going to win the Nobel Prize this year? And I said, well, I don't know.
So that was a little bit on my mind, and I looked at my cell phone and I saw a single email that
said Nobel Prize in the subject line. That wasn't enough evidence that anything had happened.
I thought, well, maybe this year they're sending out the announcement of the prize to members of
all national academies, whom they frequently consult by email. Then I opened the message,
and it was a letter that said that I had won the Nobel Prize, and that was very exciting.
So I hurried downstairs and I decided I ought to confirm it on the web. I tried to get into
the NobelPrize.org site, but there was too much traffic. So soon I went to Google News
and I googled my name, and initially there was nothing, just the usual.
Shaw Prize, probably.
I think that was there, but nothing about the Nobel Prize. So I thought,
well, it really was a hoax. But I refreshed the browser, and within about 30 seconds,
there were 100 or so articles about me, and so I knew it was true.
And first I called Betsy Layton, my administrative manager who had been with me for the last
25 years or so, and she started crying when she heard the news.
And soon after, I called my brother Earl, and he didn't answer because he was asleep,
but I left a message on his phone saying that indeed I had won the Nobel Prize this year,
and I was only telling him because he had asked about it, because I'm a very modest person after
all.
Sort of a thumb in the nose to him, right?
So before you won, you had decided to go back to Dallas after your years at Scripps.
Yes, that's right.
Why?
Well, I had enjoyed my years at Scripps. It was there that I set up a forward genetics program,
which was very successful. And at the same time, I was the chair of a small department of genetics,
and I had in mind to make a department that was all devoted to the genetics of
immunity and recruit people to join me and to capitalize on the mutagenesis effort
that we had started. But it didn't seem possible for financial reasons at Scripps.
There was just no money to recruit faculty, and I thought I didn't want to preside over
something that would not be successful, and began looking around at that point.
I did look at numerous institutions and received offers from several of them,
and UT Southwestern was one of those. And it seemed to me to be the best scientifically
and also in terms of the plan I had in mind, being a place with such a strong genetic heritage.
And also, I was very familiar with it. I liked many of the people there.
They were old friends. It was very easy to go back to Dallas, and so I did.
Well, speaking of your forward genetic screens that you started to play around with when you
were in California, you even hit on some random things related to hearing or related to
voltage channels.
Yeah, metabolism and voltage channels in the heart, the Cure 6.1.
None of those took you off course?
They really were tempting in a way, and we did work on them to some degree.
And it did absorb some of our energy, but I've learned it's really important to concentrate.
And if you begin veering off in wild directions where you're not deeply familiar with the
background of the field, you're likely to accomplish quite a bit less.
So perhaps I'm not as eclectic as my father in some sense, and I thought best to make
very deep inroads rather than a lot of shallow ones.
So more of an inch wide and a mile deep than an inch deep and a mile wide, I guess.
Yes, absolutely.
So speaking again of the genetics, why do you love it so much?
Well, there is something wonderfully compelling about starting with a phenotype and then explaining
it.
And people will tell you, at least they always used to tell me, that you have to start with
a hypothesis in biology.
And frankly, nobody should believe that because it's never been what genetics is.
In genetics, you start with a phenomenon, as we all do, something you're interested
in.
You create an exception to the phenomenon by making a phenotype.
And then you can track it down.
You find where the mutation is, exactly the molecular change that created this altered
state.
And then you know something that you didn't know before.
And the wonderful thing about this is it's a process that's completely free of bias.
And I think that is where most people get into trouble in biology.
People make hypotheses.
Somehow they invest their personal prestige in the hypothesis.
They want very badly to be right, and they don't police the hypothesis really well enough.
They don't test it quite stringently enough, or they somehow arrange the conditions subconsciously
or otherwise so that they do come out looking right.
And that's where most error comes from, in my opinion.
It's not always simply a question of interpretation, but people like to be right rather than wrong.
And this doesn't come up in genetics.
It's very logical.
It's very logical, very methodical, and very unbiased.
That's the key thing.
You take great pains in your autobiography accompanying your Nobel Prize to talk about
the dedication your students and your postdoctoral fellows had in this project,
and the workmanlike hours that they had to put in here.
How did you keep them motivated?
I mean, well, beyond how did you keep your own self motivated,
what's the key towards getting the best out of your trainees and keeping them motivated?
Well, I would say, first of all, that not all of them were, but several of them were.
Several of them were heroic.
And I believe that they felt just as I did about the project.
They were obsessive people, as I tend to be.
And once they had invested a certain amount of labor into this project,
once they saw that there was inexorable progress toward finding the mutation,
and given that they believed in genetics, as I do, they couldn't turn their backs on it.
And it's something that is quite motivating.
I didn't, let's say, have to stand over any of them with a cane.
They certainly wanted to do this, and they got deeply committed to it.
Well, I have to say, you must have had some role in motivating them.
It can't just be that you were lucky enough to find some good students.
If I had any role, it was probably in reinforcing how important the question was.
And that I would attribute to my MD background.
I knew how important LPS was.
I had seen people die of endotoxic shock, quite a number of them.
And I knew that the central question of self-non-self discrimination
at the innate level was one of the most important questions in immunology.
So I could assure them of that.
And others perhaps didn't see it that way.
I think there were many who might have looked at that question and thought,
well, maybe it'll turn out to be a protein kinase.
Maybe it won't be particularly informative.
Probably there are a hundred ways that cells detect infection and so on.
But I didn't think that.
Would you advise any of your trainees to have the same drive and motivation you did
to go after one singular problem with the exact same kind of tenacity that you had?
Or would you tell them sometimes it's okay in a forward genetic screen when you find a mutation
that leads to an interesting finding on hearing to pursue that as well?
What advice would you give to a trainee?
I was often told by people, including once again by my father,
that I was putting all my eggs in one basket.
And this was not wise.
I should diversify my portfolio.
But I must say in retrospect, if we hadn't been focused and committed to one problem,
we probably wouldn't have gotten there.
It was just a huge industry-sized project that we undertook.
But it was also very risky.
It was risky.
But I would counsel people to undertake high-risk projects and do them serially
rather than to work in parallel with a whole lot of low-risk projects.
It's very much like what you said about an inch deep and a mile wide versus
a mile deep and an inch wide.
I would opt for the latter.
Because I think we're all out to make really important discoveries
and not incremental ones in the end.
And so I would give this advice to anyone.
Quick last question.
If you were to do it all over again, would you have chosen the same path?
I think it worked out fairly well.
Then all right, I guess I lied.
Second quick last question.
If you could choose something else that was not what you did,
what do you think you would find yourself occupying your time with now?
In terms of a career?
Yeah.
Well, if I hadn't been a biomedical researcher,
very likely I would have been some kind of a naturalist and probably a writer.
So those early walks through the wood catching butterflies
that your father teased you about certainly were impressionable.
Yes, they were.
Being a birder, it's something I hope to go back to if I ever have any time again.
It doesn't seem likely in the near future.
Not in the near future, perhaps.
But someday when my ears and eyes are still working, I hope.
Great.
Well, thank you so much for joining us today.
I really enjoyed hearing a little about your story.
Thank you very much.
